Antibody-based therapeutics against components of the IGF system

The insulin-like growth factor I (IGF-I) receptor (IGF-1R) is overexpressed in most human neoplasms tested so far. Many tumors in young patients produce high levels of the IGF-1R ligands, IGF-I and IGF-II. Given the complexity of the IGF signaling pathway, its complete inhibition may require combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yang, Dimitrov, Dimiter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518512/
https://www.ncbi.nlm.nih.gov/pubmed/23243603
http://dx.doi.org/10.4161/onci.20925
_version_ 1782252566246064128
author Feng, Yang
Dimitrov, Dimiter S.
author_facet Feng, Yang
Dimitrov, Dimiter S.
author_sort Feng, Yang
collection PubMed
description The insulin-like growth factor I (IGF-I) receptor (IGF-1R) is overexpressed in most human neoplasms tested so far. Many tumors in young patients produce high levels of the IGF-1R ligands, IGF-I and IGF-II. Given the complexity of the IGF signaling pathway, its complete inhibition may require combination therapies with antibodies targeting both IGF-1R and IGF-II.
format Online
Article
Text
id pubmed-3518512
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35185122012-12-14 Antibody-based therapeutics against components of the IGF system Feng, Yang Dimitrov, Dimiter S. Oncoimmunology Author's View The insulin-like growth factor I (IGF-I) receptor (IGF-1R) is overexpressed in most human neoplasms tested so far. Many tumors in young patients produce high levels of the IGF-1R ligands, IGF-I and IGF-II. Given the complexity of the IGF signaling pathway, its complete inhibition may require combination therapies with antibodies targeting both IGF-1R and IGF-II. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518512/ /pubmed/23243603 http://dx.doi.org/10.4161/onci.20925 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Feng, Yang
Dimitrov, Dimiter S.
Antibody-based therapeutics against components of the IGF system
title Antibody-based therapeutics against components of the IGF system
title_full Antibody-based therapeutics against components of the IGF system
title_fullStr Antibody-based therapeutics against components of the IGF system
title_full_unstemmed Antibody-based therapeutics against components of the IGF system
title_short Antibody-based therapeutics against components of the IGF system
title_sort antibody-based therapeutics against components of the igf system
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518512/
https://www.ncbi.nlm.nih.gov/pubmed/23243603
http://dx.doi.org/10.4161/onci.20925
work_keys_str_mv AT fengyang antibodybasedtherapeuticsagainstcomponentsoftheigfsystem
AT dimitrovdimiters antibodybasedtherapeuticsagainstcomponentsoftheigfsystem

Ejemplares similares